- Home
- COHN vs LPCN Comparison
COHN vs LPCN Comparison
Compare COHN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHN
- LPCN
- Stock Information
- Founded
- COHN 1999
- LPCN 1997
- Country
- COHN United States
- LPCN United States
- Employees
- COHN N/A
- LPCN N/A
- Industry
- COHN Investment Bankers/Brokers/Service
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- COHN Finance
- LPCN Health Care
- Exchange
- COHN Nasdaq
- LPCN Nasdaq
- Market Cap
- COHN 18.5M
- LPCN 19.4M
- IPO Year
- COHN N/A
- LPCN N/A
- Fundamental
- Price
- COHN $9.50
- LPCN $3.38
- Analyst Decision
- COHN
- LPCN Strong Buy
- Analyst Count
- COHN 0
- LPCN 1
- Target Price
- COHN N/A
- LPCN $10.00
- AVG Volume (30 Days)
- COHN 4.6K
- LPCN 33.0K
- Earning Date
- COHN 03-05-2025
- LPCN 03-06-2025
- Dividend Yield
- COHN 10.53%
- LPCN N/A
- EPS Growth
- COHN N/A
- LPCN N/A
- EPS
- COHN 2.35
- LPCN N/A
- Revenue
- COHN $89,555,000.00
- LPCN $7,922,926.00
- Revenue This Year
- COHN N/A
- LPCN N/A
- Revenue Next Year
- COHN N/A
- LPCN N/A
- P/E Ratio
- COHN $4.05
- LPCN N/A
- Revenue Growth
- COHN 63.18
- LPCN N/A
- 52 Week Low
- COHN $6.10
- LPCN $3.20
- 52 Week High
- COHN $12.82
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- COHN 43.32
- LPCN 30.99
- Support Level
- COHN $9.43
- LPCN $3.42
- Resistance Level
- COHN $9.79
- LPCN $3.62
- Average True Range (ATR)
- COHN 0.30
- LPCN 0.26
- MACD
- COHN 0.02
- LPCN -0.02
- Stochastic Oscillator
- COHN 37.50
- LPCN 1.61
About COHN Cohen & Company Inc.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.